Healthy subjects
Conditions
Interventions
Group 1: Atomoxetine + real-10Hz-rTMS (single dose of 60 mg Atomoxetine per os)
Group 2: Placebo + real-10Hz-rTMS
Group 3: Atomoxetine + sham-rTMS (single dose of 60 mg Atomoxetine per os)
Group 4: Pl
Sponsors
Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: healthy subjects, right handed, age between 18 - 45 years
Exclusion criteria
Exclusion criteria: left-handed, neurological diseases, psychiatric diseases, other medical diseases, brain injury, stroke, febrile seizures in the childhood, psychotropic medication, fine motor skills, implanted devices like cardiac pacemaker, any metal in the head, pregnancy, lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of motor potentials evoked by transcranial magnetic stimulation, potentials were recorded with surface EMG-electrodes from the first dorsal interosseus muscle of the left hand (peak-to-peak-amplitudes in mV): resting motor threshold, short-intracortical-inhibition, intracortical facilitation, stimulus response curve Measured by the raw data of the fingertapping task: target score (total number of correct responses), execution time (time required to the subsequent correct response in ms) | — |
Countries
Germany
Contacts
Public ContactMatthias Sczesny-Kaiser
Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH
Outcome results
None listed